This paper gives an overview of placebo-controlled studies of the effect of
corticosteroid treatment on
nasal blockage, based on objective measurements of nasal airway patency. A few studies of perennial
rhinitis have indicated that pretreatment with an intranasal
corticosteroid has a moderate effect on nasal hyperresponsiveness, measured as the
histamine-induced increase of
nasal blockage. Whereas the effect on
allergen-induced early-phase symptoms is variable, the effect on the late-phase blockage is almost complete. In
seasonal allergic rhinitis, a few studies have shown an effect of intranasal
steroids on nasal airway resistance, nasal peak flow and on acoustic rhinometry, but there are no reports on the effect in adults with perennial
rhinitis. In children with perennial disease, intranasal treatment results in increased nasal patency and, in one study, also in reduced
mouth breathing and in an increased threshold for exercise-induced bronchoconstriction. In patients with nasal polyposis, intranasal
steroids have an effect on nasal airway resistance and on nasal peak flow both before and after polypectomy. There is convincing evidence that intranasal
corticosteroids provide a better effect than
antihistamine on
nasal blockage. Amazingly, there does not appear to be any report on the effect of systemic
corticosteroid treatment on nasal airway patency, and it is therefore difficult to recommend this treatment in a rational dosage. In conclusion, there is a fairly good documentation in support of the efficacy of intranasal
steroid treatment on nasal airway patency in
rhinitis. An objective measurement of nasal airway patency ought to be the routine in controlled
rhinitis trials.